Pinometostat (EPZ-5676) is a histone methyltransferase disrupter of telomeric silencing 1-like (DOT1L) inhibitor that showed early promise in a phase 1 study in advanced leukemia, including patients with MLL-r (NCT01684150) [134]. Here, KMT2A is linked to leukemia.